SCYNEXIS, Inc. (SCYX): Price and Financial Metrics
GET POWR RATINGS... FREE!
SCYX Stock Summary
- With a price/sales ratio of 1,257.42, Scynexis Inc has a higher such ratio than 99.47% of stocks in our set.
- Revenue growth over the past 12 months for Scynexis Inc comes in at -77.73%, a number that bests only 1.83% of the US stocks we're tracking.
- The volatility of Scynexis Inc's share price is greater than that of 99.5% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Scynexis Inc, a group of peers worth examining would be GERN, CBMG, INO, MRSN, and ADAP.
- Visit SCYX's SEC page to see the company's official filings. To visit the company's web site, go to www.scynexis.com.
SCYX Stock Price Chart Interactive Chart >
SCYX Price/Volume Stats
|Current price||$7.45||52-week high||$10.25|
|Prev. close||$7.53||52-week low||$4.20|
|Day high||$7.59||Avg. volume||681,780|
|50-day MA||$7.88||Dividend yield||N/A|
|200-day MA||$7.05||Market Cap||153.70M|
SCYNEXIS, Inc. (SCYX) Company Bio
SCYNEXIS, Inc., a pharmaceutical company, develops and commercializes novel anti-infectives to address unmet therapeutic needs. Its lead product candidate includes SCY-078, which is in Phase I clinical trials of the intravenous formulation; Phase II clinical trials for the treatment of invasive candida infections; and Phase II clinical trials for unmet medical needs, such as vulvovaginal candidiasis. The company was founded in 1999 and is based in Jersey City, New Jersey.
SCYX Latest News Stream
|Loading, please wait...|
SCYX Latest Social Stream
View Full SCYX Social Stream
Latest SCYX News From Around the Web
Below are the latest news stories about Scynexis Inc that investors may wish to consider to help them evaluate SCYX as an investment opportunity.
Company presentation will highlight BREXAFEMME® (ibrexafungerp tablets), the first FDA-approved product in the ibrexafungerp development pipeline, in addition to ongoing programs in the hospital setting JERSEY CITY, N.J., June 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that Marco Taglietti, M.D., President and Chief Executive Of
SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections
BREXAFEMME® (ibrexafungerp tablets), for oral use A novel oral antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infection BREXAFEMME to receive 5-year exclusivity extension under the GAIN Act for a total of 10 years of regulatory exclusivityBREXAFEMME also protected by composition-of-matter patent until 2035Commercial launch update call is scheduled for Tuesday, June 29th @ 12pm ET JERSEY CITY, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS,
The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 12 antimicrobial drug companies.
The FDA has approved Scynexis Inc's (NASDAQ: SCYX ) Brexafemme (ibrexafungerp tablets) for oral use in patients with vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. Brexafemme represents the first approved drug in a novel antifungal class in more … Full story available on Benzinga.com
SCYX Price Returns